Tue, Oct 08 · 8:30

The value that this leading ADC event provides you is the power of insight and the connections to develop more clinically impactful ADCs.

Across four streams of learning, World ADC San Diego covers every element of ADC drug development from construct design to improving preclinical predictability and product manufacturability.

This year, you’ll hear from 85+ industry expert speakers who will give detailed presentations on: confidently predicting clinical toxicities preclinically; ADCs in combination and discovering the application outside oncology.

Don’t miss this opportunity to join your fellow scientists at the heart of the ADC community. Join 600+ of your peers, from 230 organizations for your most valuable ADC learning and networking opportunity of 2019.

"The conference is an awesome opportunity to learn what has been happening and also what to expect in the future, from both technology and business perspective"

MilliporeSigma

"This conference is the preeminent ADC conference where the top companies come to present their data and share their experiences"

Ambrx

"Very informative, focused conference on all aspects of ADC research and development"

Bayer

Across four days, over 600+ ADC stakeholders from 230 organizations will converge at World ADC to providing you with an unrivalled networking experience.

Join the ADC community to catch up with friends, meet new peers and further progress partnerships.

Prices:

Full Access Pass - Standard: USD 4547.0,
Conference plus Seminar Day - Standard: USD 3898.0,
Conference plus Workshop Day - Standard: USD 3898.0,
Conference Only - Standard: USD 2899.0,
Seminar Day Only: USD 1399.0,
Workshop Day Only: USD 1399.0

URLs:

Brochure: https://go.evvnt.com/404265-3?pid=5731

Sponsor: https://go.evvnt.com/404265-4?pid=5731

Twitter: https://go.evvnt.com/404265-5?pid=5731

Speakers: Richard Gregory, ImmunoGen; Jay Short, BioAtla; Andrew Phillips, AbbVIe; Andrew Phillips, AbbVie; Melanie Smitt, Genentech; Robert Iannone, Immunomedics; Firelli Alonso, Pfizer; Tim Lowringer; Mersana; Jay Harper, AstraZeneca; Chris Leamon, Endocyte; Greg Thurber; University of Michigan